GlassScriptPhysician profile
Colton C Prudnick
NPI 1619380334
$5,873.75
in general payments reported to CMS, 2019-2025
34 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $112 · 2021: $388 · 2022: $563 · 2023: $825 · 2024: $1,947 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101 · Education: $1,585 · Travel and Lodging: $85.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.11 |
| Education | $1,585.00 |
| Travel and Lodging | $85.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,500.00 | 2024 | |
| Boston Scientific Corporation | $1,035.24 | 2019-2025 | Ams 700, General - Female Sui |
| Axonics, INC. | $712.20 | 2021-2024 | Axonics, Bulkamid |
| Teleflex LLC | $470.45 | 2021-2024 | Urolift |
| Procept Biorobotics Corporation | $332.42 | 2022-2025 | |
| Astellas Pharma US INC | $241.45 | 2019-2022 | |
| Neotract INC. | $174.15 | 2019-2020 | |
| Abbvie INC. | $132.98 | 2024-2025 | |
| Coloplast Corp | $125.10 | 2022-2025 | Speedicath |
| Astrazeneca Pharmaceuticals LP | $121.68 | 2024-2025 | Lynparza |
| Urogen Pharma, INC. | $101.74 | 2023-2025 | Jelmyto |
| Olympus America INC. | $100.81 | 2024-2025 | Itind System |
| Antares Pharma, INC. | $99.87 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Smith+Nephew, INC. | $74.27 | 2024-2025 | Stravix Pl, Stravix |
| Medtronic, INC. | $73.66 | 2023-2025 | Ligasure, Altaviva, Interstim |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $65.00 | 2023 | Itind System |
| Urovant Sciences INC | $57.13 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $47.20 | 2025 | |
| Laborie Medical Technologies Corp. | $46.93 | 2025 | Endosheath Technology |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.05 | 2022-2023 | Xifaxan |
| Cook Medical LLC | $36.31 | 2019 | |
| Sumitomo Pharma America, INC. | $32.63 | 2023-2024 | Gemtesa |
| Janssen Biotech, INC. | $30.89 | 2024 | Erleada, Akeega |
| Cycle Pharmaceuticals INC | $26.15 | 2025 | Venxxiva |
| Calyxo, INC. | $25.82 | 2024 | Cvac Aspiration System |
| Convatec INC. | $25.38 | 2023 | |
| Verity Pharmaceuticals INC. | $25.14 | 2025 | Tlando |
| Endo USA, INC. | $22.09 | 2025 | Xiaflex |
| Edwards Lifesciences Corporation | $19.29 | 2020 | |
| Valencia Technologies Corporation | $17.50 | 2025 | Ecoin Device Kit |
| Progenics Pharmaceuticals, INC. | $17.04 | 2024 | |
| Photocure INC | $15.59 | 2024 | Cysview |
| 180 Medical, INC. | $13.39 | 2024 | |
| Halozyme INC | $13.20 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colton Prudnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.